Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 11Recurrence 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Neoplasms by Histologic Type 1Neoplasms 1Lung Neoplasms 1Leukemia, Myeloid 1Hematologic Neoplasms 1Advanced Solid Tumors 1

Interventions

tetulomab tetraxetan lu-177 2osimertinib 2fludarabine 2entinostat 2Pemetrexed 2Lutetium 2Carboplatin 2spartalizumab 1pembrolizumab 1nirogacestat 1interferon gamma-1b 1gilteritinib 1ficlatuzumab 1emvododstat 1denileukin diftitox 1atezolizumab 1Trabectedin 1Taxes 1Sunitinib 1Radiosurgery 1Oncolytic Virotherapy 1Nivolumab 1Lutetium-177 1Interleukin-2 1Interferon-gamma 1Immunotherapy 1Idarubicin 1HuMax-IL8 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms by Histologic Type × gilteritinib × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡